Follow the chain left → right, from inputs to end demand. Tap any company to trace its links.
Raw inputs
Equipment
Foundry
Chip design
Software
AI demand
—
Company details
Market cap
$16B
P/E ratio
34×
Div yield
None
EPS (2025)
$4.67
Profit margin
17%
Rev. growth
+21%
Revenue
$2.86B
Cash & investments
$2.5B
In plain English
Neurocrine is a San Diego neuroscience-focused biopharma built around one blockbuster: INGREZZA (valbenazine), the first FDA-approved pill for tardive dyskinesia, which alone is ~88% of its $2.86B in 2025 revenue. It outsources manufacturing to CDMOs, sells through a handful of drug wholesalers, and is racing to diversify — launching CRENESSITY for a rare adrenal disorder and licensing a psychiatry and epilepsy pipeline from partners like Takeda, Xenon and Nxera before INGREZZA's patents fade.
In simple terms
One drug, a rented factory, and three wholesalers
Neurocrine is a design house, not a factory. Its scientists invent the molecules; CDMOs make them; the big-three wholesalers (McKesson, Cencora, Cardinal) buy nearly all of it and push it to specialty pharmacies and doctors. INGREZZA is the pillar the whole chain rests on.
Tip · Click any company in the map to learn — in one sentence — what it actually does and why it matters.